Freenome said today that it has raised $290 million from Roche to advance its cancer early detection platform, which uses a routine blood draw.
The South San Francisco, California–based company has raised more than $1.1 billion since its founding in 2014.
Get the full story on our sister site MassDevice.
Chris Newmarker is the executive editor of WTWH Media life science's news websites and publications including MassDevice, Medical Design & Outsourcing and more. A professional journalist of 18 years, he is a veteran of UBM (now Informa) and The Associated Press whose career has taken him from Ohio to Virginia, New Jersey and, most recently, Minnesota. He’s covered a wide variety of subjects, but his focus over the past decade has been business and technology. He holds bachelor’s degrees in journalism and political science from Ohio State University. Connect with him on LinkedIn or email at cnewmarker@wtwhmedia.com.
